XClose

Early Phase Cancer Trials Programme at UCL and UCLH

Menu

Haematology - Lymphoma & CLL Trials

A LIST OF OUR EARLY PHASE Haematology (Lymphoma & CLL) TRIALS WHICH ARE OPEN TO RECRUITMENT AT UNIVERSITY COLLEGE LONDON HOSPITALS

To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked IRAS Number, which will take you to the UCLH Find a Study database.

 

ALETA-001

A cancer research UK phase I/II trial of ALETA-001 in participants who do not achieve or maintain an optimal response to anti-CD19 CAR T-cell therapy for the treatment of B cell malignancies

IRAS Number:1007028
Principal Investigator:Dr William Townsend
Drug Class/ Treatrment:ALETA-001 (CAR T-Cell Engager)
Patient Population:Non-Hodgkin Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

ALLCAR19

Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia, B-cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) Using CAR T-cells to Target CD19 (ALLCAR19)

IRAS Number:217367
Principal Investigator:Dr Claire Roddie
Drug Class/ Treatrment:

CAR T-Cell Therapy

Expressing CD19 Chimeric Antigen Receptor (CD19CAR)

Patient Population:
  • Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)
  • Chronic Lymphocytic Leukaemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Adults >/=16 years old

Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

NAVAL-1

An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

IRAS Number:1003690
Principal Investigator:Dr. Kirit Ardeshna
Drug Class/ Treatrment:Nanatinostat (Histone Deacetylase Inhibitor) + Valganciclovir (Antiviral Medication)
Patient Population:Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU)

 

On hold to recruitment

CO43805
A PHASE Ib, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB OR GLOFITAMAB IN COMBINATION WITH CC-220 AND CC-99282 IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA

IRAS Number:1005230
Principal Investigator:Dr WIlliam Townsend
Drug Class/Treatment:

Mosunetuzumab (bispecific CD20-directed CD3 T-cell engager) or Glofitamab (CD20- and CD3- Bispecific Antibody)

In Combination with CC-220 (cereblon E3 ligase modulator) + CC-99282 (E3 Ligase Modulator)

Patient Population:B-Cell Non-Hodgkin Lymphoma
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF)

 

Principal Investigator(s):

William Townsend Profile
Dr. william townsend

Consultant Haematologist